Public Statement of Pfizer's Thelin EU Marketing Authorization Withdrawal - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Public Statement of Pfizer's Thelin EU Marketing Authorization Withdrawal



The EMA has issued a statement addressing the withdrawal of the marketing authorization for Thelin, which was voluntarily withdrawn in 2010 because of a risk of serious liver injury.

Back in August 2006, the European Commission (EC) awarded the orphan designated Thelin (sitaxentan) marketing authorisation in the EU. Used to treat adults with pulmonary arterial hypertension, the endothelin receptor antagonist increases capacity for physical activity. Sixteen EU Member States consequently marketed Thelin.

On 10 Dec, 2010, Pfizer announced that it would cease clinical trials of Thelin and initiated a voluntary withdrawal of the product in the EU, Canada and Australia. Pfizer based this decision on safety information obtained from clinical trials and post-marketing reports. In a press release, the company stated: “While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk of liver injury with Thelin has been observed.” Indeed, the withdrawal followed information on two cases of fatal liver injury.

On 6 Jan. 2011, the EC issued a decision confirming the withdrawal of the marketing authorization of Thelin and the European public assessment report has been updated to reflect the change. The EMA made a public statement addressing the withdrawal on 2 Mar. 2011.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here